Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
We studied the effect of intravenous infusion of synthetic truncated GLP-1 (proglucagon 78-107-amide) on fasting and postprandial gastric acid secretion, gastric emptying, and pancreatic secretion of trypsin and lipase in eight normal volunteers using marker dilution and aspiration technique. The infusion resulted in a plasma concentration of 110 +/- 14 pmol/liter (mean +/- SEM). Truncated GLP-1 significantly inhibited postprandial acid secretion by 43 +/- 11% in spite of unchanged plasma gastrin concentration. Gastric emptying rate decreased significantly; 50% emptying time increased from 16 +/- 2 min to 30 +/- 5 min. Postprandial trypsin and lipase outputs were significantly inhibited by 47 +/- 17% and 40 +/- 9% during truncated GLP-1 infusion. Pancreatic enzyme output was linearly correlated to gastric emptying, and truncated GLP-1 did not affect this relationship, suggesting that the effect on pancreatic secretion was secondary to the effect on gastric emptying. Postprandial insulin and glucagon concentrations were similar with and without truncated GLP-1 infusion in spite of significantly lower blood glucose levels (5.2 +/- 0.2 versus 3.7 +/- 0.3), indicating that GLP-1 stimulated insulin secretion and inhibited glucagon secretion. In conclusion, our results suggest that truncated GLP-1 act as a physiological inhibitor of gastric and pancreatic functions in man.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In particular, GLP-1R agonism not only emerged as a powerful tool in the treatment of T2D and excess adiposity56, but also displayed favorable effects on the cardiovascular system57 and neurodegenerative diseases55.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [57]
In the citing paper
“GLP-1 has been shown to inhibit glucagon secretion and slow gastric emptying.5, 6”
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Physiology of the Gastrointestinal Tract
Ouyang, A. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410100162049 · Cited by 950
Mojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Self-citationMojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724
Albano, J. D. M., Ekins, R. P., Maritz, G., & Turner, R. C. (1972) · Acta Endocrinologica · doi:10.1530/acta.0.0700487 · Cited by 620
Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut
Holst, J. J., Ørskov, C., Vagn Nielsen, O., & Schwartz, T. W. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)81430-8 · Cited by 615
Self-citationØRSKOV, C., HOLST, J. J., KNUHTSEN, S., BALDISSERA, F. G. A., POULSEN, S. S., & NIELSEN, O. V. (1986) · Endocrinology · doi:10.1210/endo-119-4-1467 · Cited by 482
Self-citationØRSKOV, C., HOLST, J. J., & NIELSEN, O. V. (1988) · Endocrinology · doi:10.1210/endo-123-4-2009 · Cited by 396
Self-citationOrskov, C., Jeppesen, J., Madsbad, S., & Holst, J. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115012 · Cited by 378
Self-citation
Research works printed but not linked: 4
- Holst JJ: Enteroglucagon. Adv Metab Dis 11:392?419, 1988
- Dimagno EP: Alternations and consequences of interdigestive and poststimulatory human exocrine pancreatic secretion in health and disease. Scand J Gastroenterol 12(suppl 87): 69, 1983
- Holst JJ, Creutzfeldt M, Holm G, Jensen E, Poulsen D, Sparsø B, Schmidt A: Persistent glucagonemia after pancreatectomy in pigs. Diabete Metab 4:75?79, 1978
- Solomon TE: Control of exocrine pancreatic secretion.In Physiology of the Gastrointestinal Tract, 2nd ed. LR Johnson (ed). New York, Raven Press, 1987, pp 1173?1208
Cited by
Items 301–400 of 687
Backes, B. J., Longenecker, K. L., Hamilton, G. L., Stewart, K. D., Lai, C., Kopecka, H., von Geldern, T. W., Madar, D. J., Pei, Z., Lubben, T. H., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.01.026 · Cited by 41
Byrne, M. M., McGregor, G. P., Barth, P., Rothmund, M., Göke, B., & Arnold, R. (2001) · Digestion · doi:10.1159/000051874 · Cited by 39
Campbell, R. K. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1h459 · Cited by 44
Preclinical developments in type 2 diabetes
Lenhard, J. M., & Gottschalk, W. K. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00092-3 · Cited by 44
Keller, J., Holst, J. J., & Layer, P. (2005) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00411.2005 · Cited by 38
Self-citationHuang, P.-K., Lin, S.-X., Tsai, M., Leong, M. K., Lin, S., Kankala, R. K., Lee, C., & Weng, C. (2017) · Nanomaterials · doi:10.3390/nano7050112 · Cited by 38
Rolin, B., Deacon, C. F., Carr, R. D., & Åhrén, B. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.05.013 · Cited by 37
Search for α-helical propensity in the receptor-bound conformation of glucagon-like peptide-1
Murage, E. N., Schroeder, J. C., Beinborn, M., & Ahn, J. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.10.006 · Cited by 146
Gut: A key player in the pathogenesis of type 2 diabetes?
Muscogiuri, G., Balercia, G., Barrea, L., Cignarelli, A., Giorgino, F., Holst, J. J., Laudisio, D., Orio, F., Tirabassi, G., & Colao, A. (2018) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2016.1252712 · Cited by 37
Self-citationThe gut and food intake: an update for surgeons
Näslund, E. B., Hellström, P. M., & Kral, J. G. (2001) · Journal of Gastrointestinal Surgery · doi:10.1016/s1091-255x(01)80095-0 · Cited by 42
O'Harte, F. P. M., Gray, A. M., Abdel‐Wahab, Y. H. A., & Flatt, P. R. (1997) · Peptides · doi:10.1016/s0196-9781(97)00201-5 · Cited by 37
GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products
Guglielmi, V., & Sbraccia, P. (2016) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-016-0352-y · Cited by 42
Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies
Snyder, H. S., Sakaan, S. A., March, K. L., Siddique, O., Cholankeril, R. T., Cummings, C. D., Gadiparthi, C., Satapathy, S. K., Ahmed, A., & Cholankeril, G. T. (2018) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00050 · Cited by 42
An ‘Ayurveda-Biology’ platform for integrative diabetes management
Thottappillil, A., Kouser, S., Kukkupuni, S. K., & Vishnuprasad, C. N. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113575 · Cited by 46
Dharmalingam, M., Sriram, U., & Baruah, M. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.77571 · Cited by 39
Dods, R. L., & Donnelly, D. (2016) · Bioscience Reports · doi:10.1042/bsr20150253 · Cited by 35
On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of Type 2 diabetes mellitus.
Vilsbøll, T. (2004) · PubMed · Cited by 44
Anvari, M., Paterson, C. A., Daniel, E. E., & McDonald, T. J. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018863716749 · Cited by 41
Oxyntomodulin Inhibits Pancreatic Secretion Through the Nervous System in Rats
Anini, Y., Jarrousse, C., Chariot, J., Nagain, C., Yanaihara, N., Sasaki, K., Bernad, N., Le Nguyen, D., Bataille, D., & Roz??, C. (2000) · Pancreas · doi:10.1097/00006676-200005000-00003 · Cited by 36
Hargrove, D. M., Nardone, N. A., Persson, L. M., Parker, J. C., & Stevenson, R. W. (1995) · Metabolism · doi:10.1016/0026-0495(95)90021-7 · Cited by 36
Green, B., Gault, V., Mooney, M., Irwin, N., Bailey, C., Harriott, P., Greer, B., Flatt, P., & O'Harte, F. (2003) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0310529 · Cited by 36
The brainstem preproglucagon system in a non-human primate (Macaca mulatta)
Vrang, N., & Grove, K. L. (2011) · Brain Research · doi:10.1016/j.brainres.2011.05.002 · Cited by 37
Gaddy, D. F., Riedel, M. J., Pejawar‐Gaddy, S., Kieffer, T. J., & Robbins, P. D. (2010) · Diabetes · doi:10.2337/db09-1886 · Cited by 41
Dipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment
Janardhan, S., & Sastry, G. N. (2014) · Current Drug Targets · doi:10.2174/1389450115666140311102638 · Cited by 39
Implementation of GLP-1 Based Therapy of Type 2 Diabetes Mellitus Using DPP-IV Inhibitors
Holst, J. J. (2005) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-47920-6_33 · Cited by 39
Self-citationHarnessing the Therapeutic Potential of Glucagon-Like Peptide-1: A Critical Review
Baggio, L. L., & Drucker, D. J. (2002) · Treatments in Endocrinology · doi:10.2165/00024677-200201020-00005 · Cited by 36
Mann, R., Nasr, N., Sinfield, J., Paci, E., & Donnelly, D. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00834.x · Cited by 35
“The next big thing” in diabetes: clinical progress on DPP‐IV inhibitors
von Geldern, T. W., & Trevillyan, J. M. (2006) · Drug Development Research · doi:10.1002/ddr.20138 · Cited by 40
Dupré, J., Behme, M. T., Hramiak, I. M., & Mcdonald, T. J. (1997) · Diabetes Care · doi:10.2337/diacare.20.3.381 · Cited by 35
Cracking the combination: Gut hormones for the treatment of obesity and diabetes
Alexiadou, K., Anyiam, O., & Tan, T. (2019) · Journal of Neuroendocrinology · doi:10.1111/jne.12664 · Cited by 34
Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes
Maggs, D. G., Macdonald, I. A., & Nauck, M. A. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00737.x · Cited by 40
The contribution of incretin hormones to the pathogenesis of type 2 diabetes
Meier, J. J. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.007 · Cited by 46
Sympathetic pathways mediate GLP-1 actions in the gastrointestinal tract of the rat
Giralt, M., & Vergara, P. (1998) · Regulatory Peptides · doi:10.1016/s0167-0115(98)00010-x · Cited by 42
Broide, E., Bloch, O., Ben-Yehudah, G., Cantrell, D., Shirin, H., & Rapoport, M. J. (2013) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155413497586 · Cited by 38
Yan, P., Li, L., Yang, M., Liu, D., Liu, H., Boden, G. H., & Yang, G. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.02.030 · Cited by 33
Ileal carbohydrates inhibit cholinergically stimulated exocrine pancreatic secretion in humans
Gröger, G., Unger, A., Holst, J. J., Goebell, H., & Layer, P. (1997) · International Journal of Gastrointestinal Cancer · doi:10.1007/bf02803901 · Cited by 33
Self-citationWitte, A.-B., Grybäck, P., Jacobsson, H., Näslund, E., Hellström, P. M., Holst, J. J., Hilsted, L., & Schmidt, P. T. (2011) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2010.537680 · Cited by 33
Self-citationChyan, Y., & Chuang, L. (2007) · Recent Patents on Endocrine Metabolic & Immune Drug Discovery · doi:10.2174/187221407779814570 · Cited by 37
Ogawa, E., Hosokawa, M., Harada, N., Yamane, S., Hamasaki, A., Toyoda, K., Fujimoto, S., Fujita, Y., Fukuda, K., Tsukiyama, K., et al. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.11.077 · Cited by 35
Impact of Gastric Bypass Surgery on Gut Hormones and Glucose Homeostasis in Type 2 Diabetes
Näslund, E. B., & Kral, J. G. (2006) · Diabetes · doi:10.2337/db06-s012 · Cited by 36
Green, B., Mooney, M., Gault, V. A., Irwin, N., Bailey, C. J., Harriott, P., Greer, B., Flatt, P. R., & O'Harte, F. P. M. (2004) · Metabolism · doi:10.1016/j.metabol.2003.09.015 · Cited by 35
Yeung, C.-M., Mojsov, S., Mok, P.-Y., & Chow, B. (2002) · Endocrinology · doi:10.1210/en.2002-220694 · Cited by 33
Ghrelin Does Not Influence Gastric Emptying in Obese Subjects
Mora, M. E. V., Scarfone, A., Valenza, V., Calvani, M., Greco, A. V., Gasbarrini, A., & Mingrone, G. (2005) · Obesity Research · doi:10.1038/oby.2005.83 · Cited by 33
Gu, W., Lloyd, D. J., Chinookswong, N., Komorowski, R., Sivits, G. N., Graham, M., Winters, K. A., Yan, H., Boros, L. G., Lindberg, R. A., et al. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.179986 · Cited by 36
Akarte, A. S., Srinivasan, B. P., & Gandhi, S. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.10.003 · Cited by 33
Chaikomin, R., Wu, K., Doran, S., Meyer, J. H., Jones, K. L., Feinle‐Bisset, C., Horowitz, M., & Rayner, C. K. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.02.006 · Cited by 36
GLP-1 Receptor Agonists in Pediatric and Adolescent Obesity
Stefater‐Richards, M. A., Jhe, G., & Zhang, Y. J. (2025) · PEDIATRICS · doi:10.1542/peds.2024-068119 · Cited by 42
Cai, Y., Hu, X., Yi, B., Zhang, T., & Wen, Z. (2012) · Molecular Biology Reports · doi:10.1007/s11033-012-1961-9 · Cited by 31
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Pieters, I. C., Cahen, D. L., Diamant, M., & van Raalte, D. H. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-009579 · Cited by 30
Yin, Y., Zhou, X. E., Hou, L., Zhao, L., Liu, B., Wang, G., Jiang, Y., Melcher, K., & Xu, H. E. (2016) · Cell Discovery · doi:10.1038/celldisc.2016.42 · Cited by 31
Appetite regulation by plant-derived bioactive peptides for promoting health
Kaneko, K. (2021) · Peptides · doi:10.1016/j.peptides.2021.170608 · Cited by 34
Inhibitory effects of hyperglycaemia on fed jejunal motility: potential role of hyperinsulinaemia
Byrne, Pluntke, Wank, Schirra, Arnol'd, �. �., Göke, & Katschinski (1998) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1998.00240.x · Cited by 31
Glucagon-like peptide-1 (7–36) amide as a novel neuropeptide
Blázquez, E., Álvarez, E., Navarro, M. A., Roncero, I., de Fonseca, F. R., Chowen, J. A., & Zueco, J. A. (1998) · Molecular Neurobiology · doi:10.1007/bf02914270 · Cited by 41
Brubaker, P. L., Efendic, S., & Greenberg, G. R. (1997) · Endocrine · doi:10.1007/bf02738808 · Cited by 36
Ji, X., Xia, C., Wang, J., Su, M., Zhang, L. J., Dong, T., Li, Z., Wan, X., Li, J., Li, J. X., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.08.059 · Cited by 31
Vora, J. P., Bain, S. C., Damcı, T., Dzida, G. J., Hollander, P. A., Meneghini, L., & Ross, S. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.08.002 · Cited by 31
Calabria, A. C., Charles, L., Givler, S., & León, D. D. D. (2015) · Hormone Research in Paediatrics · doi:10.1159/000442155 · Cited by 32
Venom peptides as pharmacological tools and therapeutics for diabetes
Robinson, S. D., & Safavi-Hemami, H. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.07.001 · Cited by 33
Calissendorff, J., Gustafsson, T. P., Holst, J. J., Brismar, K., & Röjdmark, S. (2012) · Endocrine Research · doi:10.3109/07435800.2012.662662 · Cited by 32
Self-citationComposite endpoints in trials of type‐2 diabetes
Einarson, T. R., Garg, M., Kaur, V., & Hemels, M. E. H. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12226 · Cited by 30
Meece, J. (2009) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.pt2.33s · Cited by 30
Pharmacotherapy of Diabetes: New Developments
Mogensen, C. E. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6 · Cited by 37
Approach to the patient with thyroid nodules: considering GLP-1 receptor agonists
Kelly, C. A., & Sipos, J. A. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae722 · Cited by 30
Jiang, Y., Zhu, H., & Gong, F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16106 · Cited by 36
Kuritzky, L., Umpierrez, G., Ekoé, J. M., Mancillas-Adame, L., & Landó, L. F. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.10.2821 · Cited by 29
Ren, L., Cui, Q., Liu, W., Wang, L., Liao, Y., Feng, Y., Sun, W., Yang, Y., Zhang, Z., Jin, T., et al. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00930 · Cited by 30
Edholm, T., Čejvan, K., Abdel‐Halim, S. M., Efendić, S., Schmidt, P., & Hellström, P. M. (2008) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2008.01229.x · Cited by 33
Gut peptides in the treatment of diabetes mellitus
Vahl, T. P., & D’Alessio, D. A. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.3.177 · Cited by 31
Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40
Mechanisms behind GLP-1 induced weight loss
Larsen, P. J. (2008) · The British Journal of Diabetes & Vascular Disease · doi:10.1177/1474651408100525 · Cited by 28
Smedegaard, S., Kampmann, U., Ovesen, P. G., Støvring, H., & Rittig, N. (2023) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.05.012 · Cited by 28
Pelle, M. C., Provenzano, M., Zaffina, I., Pujia, R., Giofrè, F., Lucà, S., Andreucci, M., Sciacqua, A., & Arturi, F. (2021) · Life · doi:10.3390/life12010029 · Cited by 28
Mechanisms for the cardiovascular effects of glucagon-like peptide-1
Poudyal, H. (2015) · Acta Physiologica · doi:10.1111/apha.12604 · Cited by 34
New Developments in the Biology of the Glucagon‐Like Peptides GLP‐1 and GLP‐2
Drucker, D. J., Lovshin, J. A., Baggio, L. L., Nian, M., Adatia, F. A., Boushey, R. P., Liu, Y., Saleh, J., Yusta, B., & Scrocchi, L. A. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06970.x · Cited by 27
2. DPPIV Inhibition: Promising Therapy for the Treatment of Type 2 Diabetes
Wiedeman, P. E. (2007) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(06)45502-8 · Cited by 27
Longo, K. A., Govek, E. K., Nolan, A. L., McDonagh, T., Charoenthongtrakul, S., Giuliana, D. J., Morgan, K., Hixon, J., Zhou, C., Kelder, B., et al. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.183764 · Cited by 31
McIver, V. J., Mattin, L. R., Evans, G. H., & Yau, A. M. W. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0215-x · Cited by 29
Tsu, H., Chen, X., Chen, C., Lee, S., Chang, C., Kao, K.-H., Coumar, M. S., Yeh, Y.-T., Chien, C., Wang, H.-S., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0507781 · Cited by 27
On the Treatment of Diabetes Mellitus with Glucagon‐like Peptide‐1
Holst, J. J., Deacon, C. F., TOFT‐NIELSEN, M., & Knudsen, L. B. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb11193.x · Cited by 29
Self-citationGlucagon-like peptide-1: physiology and therapeutic potential
Holst, J. J. (2005) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000151395.52819.47 · Cited by 30
Self-citationGutniak, M. K., Svartberg, J., Hellström, P. M., Holst, J. J., Adner, N., & Ahrén, B. (2001) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2001.00862.x · Cited by 27
Self-citationTohno, H., Sarr, M. G., & DiMagno, E. P. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90766-1 · Cited by 27
Baldassano, S., Wang, G., Mulè, F., & Wood, J. D. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00333.2011 · Cited by 28
Human colon produces fully processed glucagon‐like peptide‐1 (7–36) amide
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)00983-g · Cited by 24
Self-citationGreen, B., Gault, V. A., Irwin, N., Mooney, M. H., Bailey, C. J., Harriott, P., Greer, B., Flatt, P. R., & O'Harte, F. P. M. (2003) · Biological Chemistry · doi:10.1515/bc.2003.171 · Cited by 28
Plamboeck, A., Veedfald, S., Deacon, C. F., Hartmann, B., Vilsbøll, T., Knop, F. K., & Holst, J. J. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00123.2015 · Cited by 25
Self-citationMize, D. L. E., & Salehi, M. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0377-9 · Cited by 24
Ghrelin Is a Regulator of Glucagon-Like Peptide 1 Secretion and Transcription in Mice
Lindqvist, A., Shcherbina, L., Fischer, A.-H. T., & Wierup, N. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00135 · Cited by 29
Effect of Exogenous Insulin and Glucagon on Exocrine Pancreatic Secretion in Rats In Vivo
Ferrer, R., Medrano, J., Diego, M., Calpena, R., Graells, L., Moltó, M., Pérez, T. D. J. M., Pérez, F., & Salido, G. M. (2000) · International Journal of Gastrointestinal Cancer · doi:10.1385/ijgc:28:1:67 · Cited by 24
Ayachi, S. E., Borie, F., Magous, R., Sasaki, K., Le Nguyen, D., Bali, J. ‐., Millat, B., & Jarrousse, C. (2005) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2004.00628.x · Cited by 24
Huang, G., Li, J., Fu, H., Yan, Z., Bu, G., He, X., & Wang, Y. (2012) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2012.01.005 · Cited by 26
Study of Postprandial Lipaemia in Type 2 Diabetes Mellitus: Exenatide versus Liraglutide
Voukali, M., Kastrinelli, I., Stragalinou, S., Tasiopoulou, D., Paraskevopoulou, P., Katsilambros, N., Kokkinos, A., Tentolouris, N., & Ioannidis, I. (2014) · Journal of Diabetes Research · doi:10.1155/2014/304032 · Cited by 24
The spectrum of antidiabetic actions of GLP-1 in patients with diabetes
Vilsbøll, T., Holst, J. J., & Knop, F. K. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.011 · Cited by 25
Self-citationFung, L. C., Chisholm, C., & Greenberg, G. R. (1998) · Endocrinology · doi:10.1210/endo.139.1.5700 · Cited by 24
Shibata, C. (2001) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655201750422648 · Cited by 23
Yamanouchi, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010027 · Cited by 40
Understanding the Cardiovascular Effects of Incretin
Yoon, J. S., & Lee, H. W. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.5.437 · Cited by 25
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Pieters-van den Bos, I. C., Vendrik, K. E. W., Hoekstra, T., Bruno, M. J., Diamant, M., van Raalte, D. H., et al. (2017) · Diabetes Care · doi:10.2337/dc16-0836 · Cited by 23
Mussa, B. M., Sood, S. K., & Verberne, A. J. M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i34.3821 · Cited by 24
Janus, C., Vistisen, D., Amadid, H., Witte, D. R., Lauritzen, T., Brage, S., Bjerregaard, A., Hansen, T. F., Holst, J. J., Jørgensen, M. E., et al. (2019) · Endocrine Connections · doi:10.1530/ec-19-0408 · Cited by 24
Self-citation
Metadata
- Authors
- Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Venue
- Digestive Diseases and Sciences
- Published
- 1993-04
- Volume
- 38
- Issue
- 4
- Pages
- 665-673
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W2087063469
- Cited by
- 670
- References
- 39
- Citations by year
- 2026: 12 · 2025: 10 · 2024: 20 · 2023: 9 · 2022: 14 · 2021: 22 · 2020: 10 · 2019: 19 · 2018: 17 · 2017: 18 · 2016: 23 · 2015: 27 · 2014: 25 · 2013: 21 · 2012: 25
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Digestive Diseases and Sciences (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- gastric acid secretion, gastric emptying, postprandial insulin secretion, glucagon secretion, blood glucose, gastrin, incretins
- MeSH terms
- Adult, Depression, Chemical, Female, Gastric Acid, Gastric Emptying, Gastric Mucosa, Glucagon, Humans, Infusions, Intravenous, Lipase, Male, Pancreas, Peptide Fragments, Protein Precursors, Random Allocation, Reference Values, Time Factors, Trypsin, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.